TSWM
LYEL icon

Tyler-Stone Wealth Management’s Lyell Immunopharma LYEL Stock Holding History

Tyler-Stone Wealth Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43
Closed -$1.23K – 682
2024
Q2 		$1.23K Buy
+43
New +$2.05K ﹤0.01% 891

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tyler-Stone Wealth Management's LYEL Position: Q3 2024 in Review

Tyler-Stone Wealth Management sold out of Lyell Immunopharma (LYEL) in Q3 2024, closing a stake of 43 shares — an estimated $1.23K sold.

Tyler-Stone Wealth Management first reported a position in LYEL in Q2 2024 and held it in 1 quarter. The position peaked at $1.23K in Q2 2024. 117 funds tracked by Wall St. Rank hold LYEL as of Q3 2024.

  • Tyler-Stone Wealth Management reported no remaining Lyell Immunopharma position as of Q3 2024 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 43 Lyell Immunopharma shares in Q3 2024, an estimated $1.23K.
  • Tyler-Stone Wealth Management first reported a position in Lyell Immunopharma in Q2 2024 and held it in 1 quarter.
  • Tyler-Stone Wealth Management's Lyell Immunopharma position peaked at $1.23K in Q2 2024.
  • 117 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2024.

Based on Tyler-Stone Wealth Management's 13F filing for Q3 2024, filed 4 Nov 2024.